Business Description
Ionis Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US4622221004
Description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.72 | |||||
| Equity-to-Asset | 0.22 | |||||
| Debt-to-Equity | 2.18 | |||||
| Debt-to-EBITDA | -5.83 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 1.32 | |||||
| Beneish M-Score | -3.11 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 1.7 | |||||
| 3-Year EBITDA Growth Rate | -27.4 | |||||
| 3-Year EPS without NRI Growth Rate | 2.8 | |||||
| 3-Year FCF Growth Rate | -298.6 | |||||
| 3-Year Book Growth Rate | -20.3 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 58.03 | |||||
| 9-Day RSI | 48.1 | |||||
| 14-Day RSI | 44.47 | |||||
| 6-1 Month Momentum % | 5.12 | |||||
| 12-1 Month Momentum % | -21.15 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.91 | |||||
| Quick Ratio | 8.82 | |||||
| Cash Ratio | 8.15 | |||||
| Days Inventory | 988.61 | |||||
| Days Payable | 440.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.9 | |||||
| Shareholder Yield % | -10.59 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 98.7 | |||||
| Operating Margin % | -46.12 | |||||
| Net Margin % | -44.68 | |||||
| FCF Margin % | -46.6 | |||||
| ROE % | -93.21 | |||||
| ROA % | -12.41 | |||||
| ROIC % | -65.41 | |||||
| ROC (Joel Greenblatt) % | -110.79 | |||||
| ROCE % | -10.67 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.52 | |||||
| PB Ratio | 8.55 | |||||
| Price-to-Tangible-Book | 8.55 | |||||
| EV-to-EBIT | -16.82 | |||||
| EV-to-Forward-EBIT | -6.9 | |||||
| EV-to-EBITDA | -18.34 | |||||
| EV-to-Forward-EBITDA | -7.1 | |||||
| EV-to-Revenue | 5.66 | |||||
| EV-to-Forward-Revenue | 5.87 | |||||
| EV-to-FCF | -12.15 | |||||
| Price-to-Median-PS-Value | 0.62 | |||||
| Price-to-Net-Current-Asset-Value | 19.2 | |||||
| Price-to-Net-Cash | 87.56 | |||||
| Earnings Yield (Greenblatt) % | -5.95 | |||||
| FCF Yield % | -6.6 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IONS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ionis Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 803.066 | ||
| EPS (TTM) ($) | -2.44 | ||
| Beta | 0.07 | ||
| Volatility % | 39.46 | ||
| 14-Day RSI | 44.47 | ||
| 14-Day ATR ($) | 1.402388 | ||
| 20-Day SMA ($) | 36.732 | ||
| 12-1 Month Momentum % | -21.15 | ||
| 52-Week Range ($) | 33.33 - 54.4446 | ||
| Shares Outstanding (Mil) | 157.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ionis Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ionis Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ionis Pharmaceuticals Inc Frequently Asked Questions
What is Ionis Pharmaceuticals Inc(IONS)'s stock price today?
The current price of IONS is $35.90. The 52 week high of IONS is $54.44 and 52 week low is $33.33.
When is next earnings date of Ionis Pharmaceuticals Inc(IONS)?
The next earnings date of Ionis Pharmaceuticals Inc(IONS) is 2025-02-21 Est..
Does Ionis Pharmaceuticals Inc(IONS) pay dividends? If so, how much?
Ionis Pharmaceuticals Inc(IONS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers